InterStim Therapy for Bowel Control Recently Approved by the U.S. FDA MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) announced today that newly published data from a multicenter, ...

DUBLIN - July 17, 2017 - Medtronic plc (MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of life ...

A new multicenter study shows use of Medtronic’s InterStim Therapy via sacral nerve stimulation reduced incontinent episodes and improved quality of life in most patients with chronic fecal ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

One of the world's largest medical technology, services and solutions companies, Medtronic plc MDT is making efforts to expand its Pelvic Health & Gastric Therapies business, part of the company's ...

Medtronic’s InterStim Therapy achieved through sacral nerve stimulation helped reduce incontinent episodes in victims suffering severe fecal incontinence. The device was found to be safe and effective ...

InterStim Therapy is a sacral neuromodulation therapy from Medtronic. InterStim has been regularly used for urinary incontinence for more than a decade, but recently received additional approval as ...

Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with Bladder and Bowel Control Issues SureScan™ MRI Leads Will Provide Full-Body MRI Conditional Labeling The rechargeable ...

A new procedure is now available for the treatment of chronic bowel incontinence, a disorder impacting the lives of more than 18 million Americans. A new procedure is now available for the treatment ...

InterStim therapy is an implanted stopwatch-sized device that acts as a 'pacemaker' by determining the rate of firing of the muscles in the pelvic floor and can change the way the bladder and ...

October 22, 2008--MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT), today announced that it has submitted its Pre-Market Approval (PMA) application with the U.S. Food and Drug Administration ...